Most commonly reported underlying health conditions were diabetes, chronic lung disease, CVD.
The decision to stop the trial was made based on positive efficacy data following a recommendation from the study’s independent DMC.
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
The Centers for Disease Control and Prevention has updated the guidance for evaluation of persons under investigation for coronavirus disease 2019 (COVID-19), expanding the criteria to a wider group of symptomatic patients.
The FDA has granted Breakthrough Therapy designation to apabetalone (Resverlogix Corp) in combination with standard of care therapy, including high-intensity statins, for the secondary prevention of major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus and recent acute coronary syndrome.
The FDA has approved Trulicity (dulaglutide; Lilly) to reduce the risk of major adverse cardiovascular events (MACE; cardiovascular death, nonfatal myocardial infarction [MI], or nonfatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Patients with higher comorbidity burden more likely to be treated with insulin for T2DM.
Findings show benefit for cardiovascular disease in patients with type 2 diabetes regardless of kidney function.
Genetically higher testosterone level generally benefits men, harms women in metabolic diseases.
Linagliptin was not associated with an increased risk of adverse cardiovascular (CV) events, renal events or hypoglycemia in older patients with type 2 diabetes, according to subgroup analysis from the phase 4 Carmelina® trial.